Up to 60% of patients with clinically localized prostate cancer will relapse despite potentially curative local treatment. Current staging tests have been limited in adequately identifying individual patients who are at a high risk for future relapse. Detection of bone marrow micrometastases may ide
Identification of bone marrow micrometastases in patients with prostate cancer
β Scribed by David P. Wood Jr.; Evelyn R. Banks; Suzanne Humphreys; J. William McRoberts; Vivek M. Rangnekar
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 880 KB
- Volume
- 74
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The case of a 7-year-old boy presenting at diagnosis with a localized (stage 111) Wilms' tumor of favorable histology is presented. lmmunocytologic analysis of bone marrow aspirates revealed cells positive for neural cell adhesion molecule (NCAM) and negative for class I major histocompatibility com
## Abstract Our study evaluates the prognostic significance of the cytokeratinβpositive mononuclear cells (CK+ cells) in the bone marrow (BM) and peripheral blood (PB) as detected by immunocytochemistry in patients with locoregionally confined prostate cancer. BM and PB samples were obtained from 6
We have previously developed a quantitative PCR (QPCR) technique for the detection of cytokeratin 19 (CK19) transcripts in blood and bone marrow and compared this to immunocytochemistry (ICC). Together, both have shown promise for monitoring therapeutic efficacy in patients with metastatic breast ca